Abdulla A. Damluji, MD, PhD Profile picture
Nov 4, 2021 6 tweets 3 min read Read on X
Radiance-HTN TRIO (investigative device)

Renal denervation

Elevated BP on 3 anti-hypertensives

Randomized (blinded)

Renal denervation vs sham

Follow-up for 6 months

Outcome BP and medication burden

#TCT2021
Tough design
Med adherence
Results
Difficult data for the denervation
Conclusion

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Abdulla A. Damluji, MD, PhD

Abdulla A. Damluji, MD, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DrDamluji

Sep 7
Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis: @TheLancet

🥸Plavix for secondary prevention may be superior to aspirin

😱 Summary

👇👇👇 Image
🥸1️⃣ For decades, aspirin has been the default long-term therapy for preventing recurrent cardiovascular events in patients with established coronary artery disease. It has been embedded in clinical guidelines based largely on historical data.
🥸2️⃣ However, multiple randomized trials have recently compared clopidogrel directly with aspirin as a single-agent strategy. This 2025 meta-analysis provides the most comprehensive assessment to date by combining patient-level data.
Read 21 tweets
Sep 3
Global Uptake of GLP-1 Receptor Agonists in Obese, Non-Diabetic Patients with Cardiovascular Disease: @ESC_Journals

🥸New publication from our @heartwiselab research group: @MichaelGNanna

😱Older adults use: 1.9% of semaglutide and 1.3% of tirzepatide - summary

👇👇👇 Image
🥸1️⃣ GLP-1 receptor agonists (GLP-1RAs) were originally developed for diabetes and weight loss. SELECT expanded their role, showing semaglutide reduces cardiovascular events in non-diabetic patients with obesity and established cardiovascular disease.
🥸2️⃣ SELECT enrolled 17,604 adults ≥45 years with overweight or obesity (BMI ≥27) and prior MI, stroke, or PAD, but no diabetes. Semaglutide led to a 20% relative risk reduction in major adverse cardiovascular events.
Read 21 tweets
Aug 30
Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias: @NEJM

🥸 The statement: "Keep K above 4 and Mg above 2" still holds: #ESCCongress2025

😱 Summary

👇👇👇 Image
🥸1️⃣ The POTCAST trial tested if raising potassium to the high-normal range (4.5–5.0 mmol/L) reduces malignant arrhythmias, hospitalizations, or death in patients with cardiovascular disease and an implanted defibrillator.
🥸2️⃣ It was a randomized, multicenter trial in Denmark enrolling 1,200 patients with potassium ≤4.3 mmol/L and an implantable cardioverter-defibrillator for primary or secondary prevention.
Read 21 tweets
Aug 30
Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction: @NEJM #ESCCongress2025

🥸 Does REBOOT-CNIC agree with BETAMI-DANBLOCK?

👇👇👇 Image
🥸1️⃣ The REBOOT trial evaluated beta-blockers after MI in patients with LVEF >40%. The trial tested whether routine beta-blockers reduce death, reinfarction, or heart failure hospitalization.
🥸2️⃣REBOOT enrolled 8,438 patients with recent MI and LVEF >40%, across 109 centers in Spain and Italy. All underwent coronary angiography and received modern secondary prevention therapy. The design was PROBE: randomized, open-label, blinded endpoint adjudication.
Read 21 tweets
Aug 30
Beta-Blockers after Myocardial Infarction in Patients without Heart Failure: @NEJM @ESCCongress

🥸 Is evidence still in favor of beta blockers post AMI? #ESCCongress2025

😱Summary

👇👇👇 Image
🥸 1️⃣ The BETAMI–DANBLOCK trial, a large, pragmatic randomized trial from Denmark and Norway, asked whether long-term beta-blockers reduce death or cardiovascular events in post-MI patients with preserved or mildly reduced LVEF but no heart failure.
🥸 2️⃣ 5,574 patients with recent MI and LVEF ≥40% were randomized 1:1 to beta-blocker therapy or no beta-blockers within 14 days of the event, with outcomes tracked using complete national registry data and blinded adjudication.
Read 22 tweets
Aug 13
Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial: @ESC_Journals

🥸Aspirin for primary prevention for older pts = MACE!

👇👇👇👇 Image
🥸1️⃣ ASPREE was a large randomized trial designed to evaluate whether daily low-dose aspirin prevents cardiovascular events in initially healthy older adults.
🥸2️⃣ ASPREE enrolled 19,114 community-dwelling adults ≥70 (≥65 for US minorities), free of prior cardiovascular disease, dementia, or disability. Participants were randomized to 100 mg aspirin or placebo and followed in-trial (median 4.7 yrs) and post-trial (median 4.3 yrs).
Read 21 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(